Gene: GIPR
Official Full Name: gastric inhibitory polypeptide receptorprovided by HGNC
Gene Summary: This gene encodes a G-protein coupled receptor for gastric inhibitory polypeptide (GIP), which was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release in the presence of elevated glucose. Mice lacking this gene exhibit higher blood glucose levels with impaired initial insulin response after oral glucose load. Defect in this gene thus may contribute to the pathogenesis of diabetes. [provided by RefSeq, Oct 2011]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO07590 | GIPR Knockout cell line (HCT 116) | Human | GIPR | 1:2~1:4 | Negative | Online Inquiry |
GIPR Gene Knockout Cell Lines are specialized cell lines engineered to possess a targeted disruption of the glucagon-like peptide-1 receptor (GIPR) gene. This innovative product serves as an invaluable tool for researchers investigating the physiological roles of GIPR in metabolic processes, glucose homeostasis, and its implications in various metabolic disorders such as obesity and type 2 diabetes. By utilizing CRISPR/Cas9 technology, these cell lines allow for precise gene editing, ensuring the removal or modification of GIPR without affecting neighboring genes, thus maintaining genetic integrity for downstream experiments.
The primary mechanism by which GIPR Gene Knockout Cell Lines function lies in their ability to elucidate the receptor's signaling pathways and its impact on cellular responses, particularly in pancreatic beta cells and adipose tissues. Researchers can explore the effects of GIPR knockout on insulin secretion, energy expenditure, and overall metabolic regulation, providing insights into novel therapeutic targets for metabolic diseases.
The scientific importance of GIPR Gene Knockout Cell Lines extends to both fundamental research and clinical applications. Their versatility makes them ideal for drug discovery, allowing assessment of how potential therapeutics may interact with the GIPR signaling pathway. Furthermore, they can be employed in preclinical models to evaluate metabolic outcomes, thus facilitating translational research.
What sets our GIPR Gene Knockout Cell Lines apart from alternatives is their high level of specificity and reproducibility. Each cell line is extensively validated, ensuring reliable and consistent results in various experimental settings. Additionally, our comprehensive support and user documentation empower researchers to optimize their studies efficiently.
For researchers and clinicians committed to advancing diabetes and metabolic disorder research, GIPR Gene Knockout Cell Lines represent an essential asset. Our company's expertise in gene editing and commitment to quality ensures that you gain access to superior biological products, enabling groundbreaking discoveries and innovations within the scientific community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.